WO2018042343A3 - Composés inhibant les protéases 3c et 3cl et leurs méthodes d'utilisation - Google Patents

Composés inhibant les protéases 3c et 3cl et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2018042343A3
WO2018042343A3 PCT/IB2017/055206 IB2017055206W WO2018042343A3 WO 2018042343 A3 WO2018042343 A3 WO 2018042343A3 IB 2017055206 W IB2017055206 W IB 2017055206W WO 2018042343 A3 WO2018042343 A3 WO 2018042343A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
proteases
inhibit
specifically
Prior art date
Application number
PCT/IB2017/055206
Other languages
English (en)
Other versions
WO2018042343A2 (fr
Inventor
Janos Botyanszki
John G. Catalano
Pek Yoke Chong
Hamilton Dickson
Qi Jin
Anna LEIVERS
Andrew Maynard
Xiangmin Liao
John Miller
John Brad Shotwell
Vincent Wing-Fai TAI
Reema Thalji
Original Assignee
Glaxosmithkline Intellectual Property (No.2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No.2) Limited filed Critical Glaxosmithkline Intellectual Property (No.2) Limited
Publication of WO2018042343A2 publication Critical patent/WO2018042343A2/fr
Publication of WO2018042343A3 publication Critical patent/WO2018042343A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés, en particulier des inhibiteurs de protéase, plus particulièrement des inhibiteurs de protéase 3C et 3CL, destinés au traitement d'infections virales, et des méthodes de préparation et d'utilisation de tels composés.
PCT/IB2017/055206 2016-08-30 2017-08-30 Composés inhibant les protéases 3c et 3cl et leurs méthodes d'utilisation WO2018042343A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662381560P 2016-08-30 2016-08-30
US62/381,560 2016-08-30
US201662382410P 2016-09-01 2016-09-01
US62/382,410 2016-09-01

Publications (2)

Publication Number Publication Date
WO2018042343A2 WO2018042343A2 (fr) 2018-03-08
WO2018042343A3 true WO2018042343A3 (fr) 2018-04-19

Family

ID=59966793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/055206 WO2018042343A2 (fr) 2016-08-30 2017-08-30 Composés inhibant les protéases 3c et 3cl et leurs méthodes d'utilisation

Country Status (3)

Country Link
TW (1) TW201817714A (fr)
UY (1) UY37381A (fr)
WO (1) WO2018042343A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818691A (zh) * 2018-08-09 2020-02-21 中国科学院上海药物研究所 酮酰胺类化合物及其制备方法、药物组合物和用途
EP4098258A4 (fr) * 2020-01-31 2024-02-28 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Utilisation pharmaceutique d'un composé à base de cétoamide
WO2021191827A1 (fr) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Dérivés tripeptidiques pour le traitement d'infections par le sras-cov-2
EP4125919A1 (fr) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales
US20230131564A1 (en) * 2020-04-10 2023-04-27 Cocrystal Phaema, Inc. Inhibitors of norovirus and coronavirus replication
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
US11124497B1 (en) 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
EP4146267A1 (fr) * 2020-05-08 2023-03-15 The Board of Trustees of the Leland Stanford Junior University Inhibiteurs de protéase pour le traitement ou la prévention d'une maladie à coronavirus
US11174231B1 (en) 2020-06-09 2021-11-16 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
EP4178955A1 (fr) 2020-07-11 2023-05-17 Pfizer Inc. Dérivés d'hétéroaryl cétone antiviraux
ES2936277R1 (es) 2020-07-20 2023-04-18 Enanta Pharm Inc Peptidos funcionalizados como agentes antivirales
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CA3173333A1 (fr) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux derives de spiropyrrolidine
CA3202764A1 (fr) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux derives de spiropyrrolidine
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3204314A1 (fr) * 2020-12-18 2022-06-23 Heptares Therapeutics Limited Composes inhibiteurs de mpro du sars-cov-2
WO2022208262A1 (fr) * 2021-03-30 2022-10-06 Pfizer Inc. Composés antiviraux à liaison éther
TW202304859A (zh) * 2021-04-01 2023-02-01 美商普姆治療公司 Sars-3cl蛋白酶抑制劑
IL307443A (en) * 2021-04-16 2023-12-01 Fujian Akeylink Biotechnology Co Ltd A short ring-modified peptide compound of proline and its use
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
WO2022265577A2 (fr) * 2021-06-15 2022-12-22 Agency For Science, Technology And Research Modulateurs d'enzyme du coronavirus, leurs procédés de synthèse et leurs utilisations
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물
CN113773259A (zh) * 2021-07-14 2021-12-10 上海药明康德新药开发有限公司 病毒主蛋白酶抑制剂及其制备方法和用途
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023003610A1 (fr) * 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
CN114149415A (zh) * 2021-07-26 2022-03-08 中国药科大学 一种拟肽类化合物及其衍生物、制备方法、药物组合物和应用
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023009187A1 (fr) * 2021-07-29 2023-02-02 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
CN117836272A (zh) * 2021-08-02 2024-04-05 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶小分子抑制剂及其用途
CN115594734B (zh) * 2021-09-09 2023-03-17 广东众生睿创生物科技有限公司 酮酰胺衍生物及其应用
WO2023043816A1 (fr) * 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus
WO2023044171A1 (fr) * 2021-09-20 2023-03-23 Pardes Biosciences, Inc. Inhibiteurs de cystéine protéases et leurs méthodes d'utilisation
WO2023051657A1 (fr) * 2021-09-30 2023-04-06 中国科学院上海药物研究所 Composé cyano, son procédé de préparation et son utilisation
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086400A1 (fr) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
WO2023107419A1 (fr) * 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Composés spirocycliques saturés utilisés comme agents antiviraux
US20230174542A1 (en) * 2021-12-08 2023-06-08 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
WO2023149982A1 (fr) * 2022-02-07 2023-08-10 Purdue Research Foundation Composés pour le traitement du sars
CN114957383A (zh) * 2022-04-01 2022-08-30 中国科学院上海药物研究所 一种拟肽类化合物及其制备方法、药物组合物和用途
WO2024078294A1 (fr) * 2022-10-13 2024-04-18 广东众生睿创生物科技有限公司 Forme amorphe de dérivé de cétoamide et procédé pour la préparer
WO2024078302A1 (fr) * 2022-10-13 2024-04-18 广东众生睿创生物科技有限公司 Forme cristalline d'un dérivé de cétoamide et son procédé de préparation
WO2024112621A1 (fr) * 2022-11-22 2024-05-30 Merck Sharp & Dohme Llc Dérivés de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide utilisés en tant qu'inhibiteurs de protéase pour le traitement ou la prévention d'une infection à coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (fr) * 2004-12-09 2006-06-15 Pfizer Inc. Compositions et composes anti-coronaviraux, leur utilisation pharmaceutique et materiaux destines a leur synthese
WO2013049382A2 (fr) * 2011-09-27 2013-04-04 Kansas State University Research Foundation Antiviraux à large spectre contre des protéases 3c ou 3c-associées du super-groupe des picornavirus-associés : picornavirus, calicivirus et coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (fr) * 2004-12-09 2006-06-15 Pfizer Inc. Compositions et composes anti-coronaviraux, leur utilisation pharmaceutique et materiaux destines a leur synthese
WO2013049382A2 (fr) * 2011-09-27 2013-04-04 Kansas State University Research Foundation Antiviraux à large spectre contre des protéases 3c ou 3c-associées du super-groupe des picornavirus-associés : picornavirus, calicivirus et coronavirus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRIOR ALLAN M ET AL: "Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 23, 30 September 2013 (2013-09-30), pages 6317 - 6320, XP028760181, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.09.070 *

Also Published As

Publication number Publication date
TW201817714A (zh) 2018-05-16
UY37381A (es) 2018-03-23
WO2018042343A2 (fr) 2018-03-08

Similar Documents

Publication Publication Date Title
WO2018042343A3 (fr) Composés inhibant les protéases 3c et 3cl et leurs méthodes d'utilisation
WO2018195397A3 (fr) Inhibiteurs d'indole ahr et leurs utilisations
EP3848370A3 (fr) Inhibiteurs de tyk2 et leurs utilisations
WO2018006074A3 (fr) Composés et méthodes permettant de moduler la fonction de l'arn
EP4327809A3 (fr) Inhibiteurs de tyk2 et leurs utilisations
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
WO2016034591A3 (fr) Pores mutants
WO2015153889A3 (fr) Substances et procédés pour le traitement d'une infection virale latente
WO2016044463A3 (fr) Inhibiteurs de mk2 et leurs utilisations
WO2018081648A3 (fr) Anticorps anti-mic et méthodes d'utilisation
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP3846846A4 (fr) Compositions et procédés pour le traitement d'infections virales
EP3474861A4 (fr) Composés comprenant des hmos pour la prévention et/ou le traitement d'infections virales et/ou bactériennes.
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
EP3538189A4 (fr) Compositions, dispositifs et méthodes pour le traitement de conditions médiées par un récepteur des opioides
EP3655404A4 (fr) Composés et leur utilisation pour le traitement d'infections microbiennes
EP4234552A3 (fr) Inhibiteurs de la 3-phosphoglycérate déshydrogénase et leurs utilisations
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
WO2020051375A3 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.
EP3551619A4 (fr) Compositions comprenant des promédicaments méthylphénidates, procédés de fabrication et d'utilisation de ces compositions
EP3426671A4 (fr) Composés et compositions pour le traitement d'infections
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
ZA202211980B (en) Methods and treatment of trauma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17772475

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17772475

Country of ref document: EP

Kind code of ref document: A2